


CLAIMS

1. A compound represented by the formula (I):



5 wherein

Ring A is an optionally further substituted ring,

Ring D is an optionally further substituted ring,

n is 1 or 2,

X is -O-, -CR¹R²-, -CR¹R²-O-, -O-CR¹R²- or -NR³-,

10 R¹, R² and R³ are each independently a hydrogen atom or a substituent, and

R^a and R^b are each independently a hydrogen atom or a C₁₋₆ alkyl group optionally substituted by halogen atom(s), or a salt thereof.

15

2. The compound or salt of claim 1, wherein

Ring D is a cyclobutane ring;

n is 1;

X is -O-; and

20 R^a and R^b are both hydrogen atoms.

3. The compound or salt of claim 1, wherein Ring A is an optionally further substituted 3- to 14-membered non-aromatic heterocycle.

25

4. The compound or salt of claim 1, wherein

Ring A is a 3- to 14-membered non-aromatic heterocycle

optionally further substituted by 1 to 3 substituents selected from

(a) a C₁₋₆ alkyl group optionally substituted by 1 to 3 substituents selected from

(i) a C₆₋₁₄ aryloxy group optionally substituted by 1 to 3 substituents selected from

5 (I) a halogen atom,
(II) an optionally halogenated C₁₋₆ alkyl group,
(III) a C₃₋₁₀ cycloalkyl group,
(IV) a 3- to 14-membered non-aromatic heterocyclic group optionally substituted by 1 to 3 halogen atoms,
10 and

(V) a cyano group,

(ii) a C₆₋₁₄ aryl group optionally substituted by 1 to 3 substituents selected from

(I) a halogen atom, and
15 (II) an optionally halogenated C₁₋₆ alkyl group,
(iii) a halogen atom, and
(iv) a C₇₋₁₆ aralkyloxy group optionally substituted by 1 to 3 substituents selected from

(I) a halogen atom, and

20 (II) a C₁₋₆ alkyl group,

(b) a C₇₋₁₆ aralkyloxy group optionally substituted by 1 to 3 substituents selected from

(i) a halogen atom,

(ii) an optionally halogenated C₁₋₆ alkyl group, and

25 (iii) an optionally halogenated C₁₋₆ alkoxy group,

(c) a C₂₋₆ alkenyl group optionally substituted by 1 to 3 substituents selected from

(i) a C₆₋₁₄ aryl group optionally substituted by 1 to 3 substituents selected from

30 (I) a halogen atom, and

(II) an optionally halogenated C₁₋₆ alkyl group, and

(ii) a halogen atom,

(d) a C₆₋₁₄ aryloxy group optionally substituted by 1 to 3 halogen atoms, and

35 (e) a 3- to 14-membered non-aromatic heterocyclic group

optionally substituted by 1 to 3 substituents selected from

- (i) a halogen atom, and
- (ii) an optionally halogenated C₁₋₆ alkyl group;

Ring D is a C₄₋₅ cycloalkane;

5 n is 1 or 2;

X is -O-, -CH₂- or -O-CH₂-; and

R^a and R^b are both hydrogen atoms.

5. The compound or salt of claim 1, wherein

10 Ring A is

(1) an azetidine ring optionally further substituted by 1 to 3 substituents selected from

(a) a benzyloxy group optionally substituted by 1 to 3 substituents selected from

15 (i) a halogen atom, and

(ii) an optionally halogenated C₁₋₆ alkyl group,

(2) a piperidine ring optionally further substituted by 1 to 3 substituents selected from

(a) a C₁₋₆ alkyl group optionally substituted by 1 to 3 substituents selected from

20 (i) a phenoxy group optionally substituted by 1 to 3 substituents selected from

(I) a halogen atom,

(II) an optionally halogenated C₁₋₆ alkyl group, and

25 (III) an azetidinyll group optionally substituted by 1 to 3 halogen atoms,

(ii) a phenyl group optionally substituted by 1 to 3 halogen atoms, and

(iii) a halogen atom, and

30 (b) a dihydrobenzofuryl group optionally substituted by 1 to 3 substituents selected from

(i) a halogen atom, and

(ii) an optionally halogenated C₁₋₆ alkyl group, or

(3) a 7-azaspiro[3.5]nonane ring optionally further substituted
35 by 1 to 3 substituents selected from

- (a) a phenoxy group optionally substituted by 1 to 3 halogen atoms;
Ring D is a cyclobutane ring;
n is 1;
5 X is -O-; and
R^a and R^b are both hydrogen atoms.
6. The compound or salt of claim 1, wherein
Ring A is
10 (1) an azetidine ring further substituted by 1 to 3 substituents selected from
(a) a benzyloxy group substituted by 1 to 3 substituents selected from
(i) a halogen atom, and
15 (ii) an optionally halogenated C₁₋₆ alkyl group;
Ring D is a cyclobutane ring;
n is 1;
X is -O-; and
R^a and R^b are both hydrogen atoms.
- 20 7. (2s,4s)-2-((3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidin-1-yl)carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, or a salt thereof.
- 25 8. (2s,4s)-2-((3-((2-Methyl-4-(trifluoromethyl)benzyl)oxy)azetidin-1-yl)carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, or a salt thereof.
9. (2s,4s)-2-((3-((3-Chloro-4-methylbenzyl)oxy)azetidin-1-yl)carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, or a salt thereof.
- 30 10. A medicament comprising the compound or salt of claim 1.
- 35 11. The medicament of claim 10, which is a monoacylglycerol

lipase inhibitor.

12. The medicament of claim 10, which is an agent for the prophylaxis or treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, anxiety disorder, pain, epilepsy or depression.

13. Use of the compound or salt of claim 1 for the production of an agent for the prophylaxis or treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, anxiety disorder, pain, epilepsy or depression.

14. The compound or salt of claim 1 for use in the prophylaxis or treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, anxiety disorder, pain, epilepsy or depression.

15. A method of inhibiting monoacylglycerol lipase in a mammal, which comprises administering an effective amount of the compound or salt of claim 1 to the mammal.

16. A method for the prophylaxis or treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, anxiety disorder, pain, epilepsy or depression in a mammal, which comprises administering an effective amount of the compound or salt of claim 1 to the mammal.

30